A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

David A. Bond; Ying Huang; Beth A. Christian; Samantha Jaglowski; Don Benson; Lapo Alinari; Robert A. Baiocchi; Jonathon B. Cohen; Kristie A. Blum; Kami J. Maddocks

doi:10.1080/10428194.2022.2034154

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

David A. Bond, Ying Huang, Beth A. Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A. Baiocchi, Jonathon B. Cohen, Kristie A. Blum, Kami J. Maddocks

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	1750-1753
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	63
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2022.2034154
State	Published - 2022

Access to Document

10.1080/10428194.2022.2034154

Cite this

@article{dc75189cef0d4eee83a7e3a2535a86d9,

title = "A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma",

author = "Bond, {David A.} and Ying Huang and Christian, {Beth A.} and Samantha Jaglowski and Don Benson and Lapo Alinari and Baiocchi, {Robert A.} and Cohen, {Jonathon B.} and Blum, {Kristie A.} and Maddocks, {Kami J.}",

note = "Funding Information: DB has consulted for Sea Gen and Kite/Gilead. BC has received research funding from Acerta, Celgene, Genentech, Triphase, MorphoSys, and Merck and has consulted for Verastem, Sea Gen, Genentech, and Astra Zeneca. SJ has received research funding from Gilead, Novartis, and Unum and has consulted for Bristol Myers Squibb, Gilead, and Novartis. JC has received research funding from Janssen, Novartis, TG Therapeutics, Astra Zeneca, Genentech, and Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, Astra Zeneca, Loxo, and Sea Gen. KM has received research funding from Novartis, Bristol Myers Squibb, and Pharmacyclics and has consulted for Morphosys, ADC Therapeutics, Astra Zeneca, Beigene, Celgene, Gilead, and Sea Gen. All other authors declare no competing interests.",

year = "2022",

doi = "10.1080/10428194.2022.2034154",

language = "English",

volume = "63",

pages = "1750--1753",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "7",

}

TY - JOUR

T1 - A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

AU - Bond, David A.

AU - Huang, Ying

AU - Christian, Beth A.

AU - Jaglowski, Samantha

AU - Benson, Don

AU - Alinari, Lapo

AU - Baiocchi, Robert A.

AU - Cohen, Jonathon B.

AU - Blum, Kristie A.

AU - Maddocks, Kami J.

N1 - Funding Information: DB has consulted for Sea Gen and Kite/Gilead. BC has received research funding from Acerta, Celgene, Genentech, Triphase, MorphoSys, and Merck and has consulted for Verastem, Sea Gen, Genentech, and Astra Zeneca. SJ has received research funding from Gilead, Novartis, and Unum and has consulted for Bristol Myers Squibb, Gilead, and Novartis. JC has received research funding from Janssen, Novartis, TG Therapeutics, Astra Zeneca, Genentech, and Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, Astra Zeneca, Loxo, and Sea Gen. KM has received research funding from Novartis, Bristol Myers Squibb, and Pharmacyclics and has consulted for Morphosys, ADC Therapeutics, Astra Zeneca, Beigene, Celgene, Gilead, and Sea Gen. All other authors declare no competing interests.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85124363293&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2034154

DO - 10.1080/10428194.2022.2034154

M3 - Letter

C2 - 35129029

AN - SCOPUS:85124363293

SN - 1042-8194

VL - 63

SP - 1750

EP - 1753

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

Access to Document

Other files and links

Cite this